Today, Symphony Technology Group (STG) announced the closing of the sale of AlphaImpactRx, a leading provider of primary research and analytics-based insight for biopharmaceutical and consumer health companies to IMS Health, a global information and technology services company serving the healthcare industry. AlphaImpactRx’s complementary offerings, capabilities and technologies will be integrated into IMS Health to form a foundation for the company’s growing global primary market research capabilities.
AlphaImpactRx was created by STG in 2011 through the combination of ImpactRx, TargetRx, and AlphaDetail, three leading physician primary market research platforms in biopharma. The company briefly operated as a subsidiary of Symphony Health Solutions, a STG portfolio company created after the firm acquired Source Health Analytics, prior to being spun out as a separate company again at the end of 2014.
“IMS Health is a great home for our business and our people,” said John Ouren, CEO of AlphaImpactRx. “The company has a broad global platform across many different areas in healthcare and technology, and we believe those additional capabilities will enable us to better serve our clients and grow our platform,” he said.
“We’re very pleased with this result as it works well for all sides,” said J.T. Treadwell, Managing Director at Symphony Technology Group. “We created a great business in AlphaImpactRx with leadership in physician primary market research, solid financial performance, and an excellent team that we wish continued success at IMS Health. There is a tremendous amount of opportunity in healthcare analytics, and as we continue to work with our remaining portfolio companies and pursue new opportunities, we expect to develop similar success stories.”
STG’s current healthcare portfolio includes:
About Symphony Technology Group: Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great technology and services companies. In addition to capital, STG provides transformation expertise to enable its companies to deliver maximum value to their clients, to drive growth through innovation, to retain and attract the best talent and to achieve best in class business performance. STG’s current portfolio consists of 19 global companies. For more information, please visit www.symphonytg.com.
About AlphaImpactRx: AlphaImpactRx is the leading provider of primary research-based insights, analytics and solutions to pharmaceutical, consumer health and medical device companies. Through the combination of its consulting expertise, innovative technology, proprietary physician panels and syndicated data assets, AlphaImpactRx provides market research to help its global healthcare clients make informed and timely business decisions to develop and market their products. For more information, please visit www.alphaimpactrx.com.
About IMS Health: IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. Our 7,500 services experts connect configurable SaaS applications to 10+ petabytes of complex healthcare data in the IMS One™ cloud platform, delivering unique insights into diseases, treatments, costs and outcomes. The company’s 15,000 employees blend global consistency and local market knowledge across 100 countries to help clients run their operations more efficiently. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS Health uses anonymous healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes. Additional information is available at www.imshealth.com.